| Class / Patent application number | Description | Number of patent applications / Date published |
|---|
| 514538000 | Nitrogen bonded to carbon in Z moiety | 56 |
| 20080221209 | Enantiomers of amino-phenyl-acetic acid octadec-9-(z) enyl ester, their salts and their uses - Disclosed are enantiomers of amino-phenyl-acetic acid octadec-9-(Z)-enyl ester, and salts thereof, including pharmaceutical compositions, uses and a process for the manufacture thereof. | 09-11-2008 |
| 20080293810 | MULTI-DOSE CONCENTRATE ESMOLOL WITH BENZYL ALCOHOL - Disclosed are concentrate esmolol injection essentially free from other related esters of esmolol and diluted esmolol compositions. The concentrate esmolol formulation includes from about 25-1000 mg/ml of esmolol and about 1-25% w/v of benzyl alcohol and the combination thereof. The compositions can also be used as multi-dose compositions. The present invention also discloses diluted, ready-to-use compositions of esmolol prepared by dilution of the present invention concentrates. Also disclosed are methods of making and using the ready-to-use compositions of the present invention. | 11-27-2008 |
| 20090018191 | Deuterated Catecholamine Derivatives and Medicaments Comprising Said Compounds - The present invention concerns deuterated catecholamine derivatives as well as pharmaceuticals containing these compounds. In addition, the invention concerns the use of deuterated catecholamine derivatives as well as physiologically acceptable salts thereof, and also pharmaceutical compositions, which contain these compounds, also in combination with enzyme inhibitors, for the treatment of dopamine deficiency diseases or diseases which are based on disrupted tyrosine transport or disrupted tyrosine decarboxylase, as well as other disorders. | 01-15-2009 |
| 20090076145 | DEUTERIUM-ENRICHED AMIBEGRON - The present application describes deuterium-enriched amibegron, pharmaceutically acceptable salt forms thereof, and methods of treating using the same. | 03-19-2009 |
| 20090111874 | Phenyl-containing n-acyl amine and aminoacid derivatives, methods for the production thereof, a pharmaceutical composition and the use thereof - The present invention relates to novel phenyl-N-acyl derivatives of biogenic amines and amino acids of general formula (I) as cyclooxynease inhibitors, possessing analgetic and anti-inflammatory properties and devoid of side effects in particular ulcerogeneity and pro-spasmodic actions, as well as capability to potentiate effect of other analgetics, and possessing in addition antihypoxic, antidepressant and anti-Parkinsonistic action; as well as to the processes for the preparation novel and known phenyl-N-acyl derivatives of biogenic amines, to a pharmaceutical composition and to an agent comprising compounds of general formula (I) as well as to use thereof and a method of treating. | 04-30-2009 |
| 20090176878 | GENETIC POLYMORPHISMS AND SUBSTANCE DEPENDENCE - The invention encompasses a method for identifying subjects at risk for substance dependence by detecting the presence of polymorphism in the CHRNA5-CHRNA3-CHRNB4 gene cluster and the CHRNA4 gene. The invention also encompasses determining the response of a subject to a therapeutic substance, treating substance dependence in a subject, and evaluating the response of a subject to a substance cessation treatment. | 07-09-2009 |
| 20090326067 | Levodopa Prodrug Mesylate, Compositions Thereof, and Uses Thereof - (2R)-2-Phenylcarbonyloxypropyl(2S)-2-amino-3-(3,4-dihydroxyphenyl)propanoate mesylate and crystalline form thereof, methods of making the same, pharmaceutical compositions thereof, and methods of using the same to treat diseases or disorders such as Parkinson's disease are provided. | 12-31-2009 |
| 20100004332 | Levodopa Prodrugs, and Compositions and Uses Thereof - Prodrugs of levodopa, methods of making prodrugs of levodopa, methods of using prodrugs of levodopa, and compositions of prodrugs of levodopa are disclosed. | 01-07-2010 |
| 20100076079 | Pharmaceutical Compositions Of Short-Acting Sedative Hypnotic Agent - The invention provides pharmaceutical compositions comprising a phenylacetic acid ester compound useful for inducing or maintaining general anesthesia or sedation in mammals, methods for preparing such compositions, and methods for inducing or maintaining anesthesia or sedation using such compositions. | 03-25-2010 |
| 20110034552 | LONG-CHAIN OXYAMINOPOLYOL BASED GELATOR AND GEL - [Problems to be Solved] It is an object of the present invention to provide a gelator containing a long chain oxyaminopolyol capable of forming a gel with a small amount thereof over a liquid property range from acidic to alkaline, and a gel having high environmental suitability, biocompatibility and biodegradability. | 02-10-2011 |
| 20110034553 | NOVEL CONJUGATES FOR TREATING NEURODEGENERATIVE DISEASES AND DISORDERS - A conjugate comprising L-DOPA covalently linked to at least one y-aminobutyric acid (GABA) moiety, an ester and/or an addition salt thereof are disclosed, as well as uses thereof for treating a neurodegenerative disease or disorder. | 02-10-2011 |
| 20120115948 | INHIBITORS OF ANAPHASE PROMOTING COMPLEX ACTIVITY - The invention provides an anti-proliferative composition comprising a non-peptide analog of the C-terminal isoleucine-arginine (IR) tail motif of an activator of an anaphase promoting complex (APC). The invention further provides methods of inhibing the ubiquitination activity of the APC by administering compositions of the invention. | 05-10-2012 |
| 20120196930 | TOPICAL FORMULATION FOR DIABETIC FOOT ULCERS - This invention relates to a new topical gel formulation of the drug Esmolol hydrochloride for treatment of chronic wounds such as diabetic wounds, burn wounds, venous ulcers and pressure ulcers. | 08-02-2012 |
| 20120277309 | METHODS OF CONTROLLING VENOUS IRRITATION ASSOCIATED WITH THE TREATMENT OF A CARDIAC DISORDER - A pharmaceutical composition comprising (S)-methyl-3-[4-(2-hydroxy-3-isopropylamino)propoxy]phenylpropionate in a concentration between about 75 mM and about 150 mM, which is substantially free of the R-isomer or pharmaceutically acceptable salt thereof, is provided. A method of treating a cardiac disorder is also provided and includes administering to a subject in need thereof a therapeutically effective amount of a pharmaceutical composition comprising (S)-methyl-3-[4-(2-hydroxy-3-isopropylamino)propoxy]phenylpropionate hydrochloride, wherein the (S)-methyl-3-[4-(2-hydroxy-3-isopropylamino)propoxy]phenylpropionate hydrochloride is present at a concentration between about 75 mM and about 150 mM and wherein the pharmaceutical composition is substantially free of (R)-methyl-3-[4-(2-hydroxy-3-isopropylamino)propoxy]phenylpropionate or pharmaceutically acceptable salt thereof. | 11-01-2012 |
| 20120302637 | Methods of Treating Tachycardia and/or Controlling Heart Rate While Minimizing and/or Controlling Hypotension - A method of treating tachycardia while minimizing and/or controlling hypotension associated with such treatment includes administering a therapeutically effective amount of a pharmaceutical composition comprising the S-isomer of esmolol to a subject in need thereof. | 11-29-2012 |
| 20130190397 | NOVEL COMPOUND ACCELERATING SECRETION OF HUMAN-DERIVED ANTI-MICROBIAL PEPTIDE, METHOD FOR PREPARING SAME, AND COMPOSITION HAVING SAME AS ACTIVE INGREDIENT - Disclosed is a compound having an acceleration effect on the secretion of human β-defensin, LL-37, which is a human-derived anti-microbial peptide, a method for preparing same, and a composition for accelerating the secretion of anti-microbial peptide having same as an active ingredient, and the compound and the composition using same of the present invention enhance the anti-microbial effect and the immunity control effect that the anti-microbial peptide has in the body by accelerating the secretion of the anti-microbial peptide in the body. | 07-25-2013 |
| 20130253056 | Continuous Administration of Levodopa and/or Dopa Decarboxylase Inhibitors and Compositions for Same - Disclosed herein are for example, liquid aqueous compositions that include for example an ester or salt of levodopa, or an ester or salt of carbidopa, and methods for treating neurological or movement diseases or disorders such as restless leg syndrome, Parkinson's disease, secondary parkinsonism, Huntington's disease, Parkinson's like syndrome, PSP, MSA, ALS, Shy-Drager syndrome, dystonia, and conditions resulting from brain injury including carbon monoxide or manganese intoxication, using substantially continuous administration of levodopa and/or carbidopa or ester and/or salt thereof. | 09-26-2013 |
| 20140066503 | METHODS FOR TREATING TACHYCARDIA AND/OR CONTROLLING HEART RATE WHILE MINIMIZING AND/OR CONTROLLING HYPOTENSION - A method of treating tachycardia while minimizing and/or controlling hypotension associated with such treatment includes administering a therapeutically effective amount of a pharmaceutical composition comprising the S-isomer of esmolol to a subject in need thereof. | 03-06-2014 |
| 20140088192 | SUBCUTANEOUSLY INFUSIBLE LEVODOPA PRODRUG COMPOSITIONS AND METHODS OF INFUSION - The invention features methods compositions and infusion pumps for infusing levodopa prodrugs (e.g., levodopa esters, levodopa amides, levodopa carboxamides, and levodopa sulfonamides) for the treatment of Parkinson's disease. | 03-27-2014 |
| 20140194508 | SYNTHESIS, METHODS OF USING, AND COMPOSITIONS OF CYCLOALKYLMETHYLAMINES - The present invention provides novel cycloalkylmethylamine analogs, and methods of preparing cycloalkylmethylamine analogs. The present invention also provides methods of using cycloalkylmethylamine analogs and compositions of cycloalkylmethylamine analogs. The pharmaceutical compositions of the compounds of the present invention can be advantageously used for treating and/or preventing obesity and obesity related co-morbid indications. | 07-10-2014 |
| 20140221480 | METHODS OF MANAGING BRAIN INFLAMMATION - This disclosure relates to methods of managing brain injury such as inflammation due to trauma induced brain injury and ischemic stroke by administering resatorvid or derivative there of a subject in need thereof. In certain embodiments, the disclosure relates to methods of treating cerebral ischemia comprising administering an effective amount of resatorvid to a subject in need thereof. In certain embodiments, the effective amount is 3 mg/kg. In certain embodiments, resatorvid is administered by injection. | 08-07-2014 |
| 20140275249 | READY-TO-USE CO-SOLVENTS PHARMACEUTICAL COMPOSITION IN MODIFIED FLEXIBLE PLASTIC CONTAINER - A ready-to-use injectable, co-solvents (ternary mixture) pharmaceutical composition for the treatment of cardiac conditions and diagnosis applications, comprising methyl-3-[4-(2-hydroxy-3-isopropylamino) propoxy]phenylpropionate hydrochloride (Esmolol hydrochloride), a buffering agent, ethanol and propylene glycol which capable of been stored in modified flexible plastic container, heat-sterilized without deformation and/or integrity of the closure system been compromised, as well as method for its manufacture, is disclosed. | 09-18-2014 |
| 20150011630 | DIHYDROXYPHENYL NEUROTRANSMITTER COMPOUNDS, COMPOSITIONS AND METHODS - The present invention relates to new dihydroxyphenyl modulators of neurotransmitter levels, pharmaceutical compositions thereof, and methods of use thereof. | 01-08-2015 |
| 20150087704 | PARENTERAL ESMOLOL FORMULATION - A parenteral formulation of esmolol hydrochloride for use in the treatment of a patient suffering from tachycardia comprising a lyophilized powder consisting of pure esmolol hydrochloride, wherein said powder is reconstituted to obtain a ready-to-use i.v. solution of esmolol hydrochloride at a concentration of 20-100 mg/mL, and said i.v. solution is directly administered to the patient, and further a method of producing a ready-to-use i.v. solution of esmolol hydrochloride by reconstituting a lyophilized powder consisting of pure esmolol hydrochloride with a solvent, characterized in that said solvent is an i.v. solvent devoid of alcohol or a buffer excipient, in an amount necessary to obtain a ready-to-use i.v. solution at a concentration of 20-100 mg/mL, and the ready-to-use i.v. solution containing a parenteral formulation of 20-100 mg/mL pure esmolol hydrochloride in an infusion device or consisting of a parenteral formulation of 20-100 mg/mL pure esmolol hydrochloride, WFI and/or saline solution, devoid of any alcohol or buffer excipients. | 03-26-2015 |
| 20150376117 | POSITION-SPECIFIC ASYMMETRIC DEUTERIUM ENRICHED CATECHOLAMINE DERIVATIVES AND MEDICAMENTS COMPRISING SAID COMPOUNDS - Herein described are deuterated catecholamine derivatives of the general Formula (I) wherein R | 12-31-2015 |
| 514539000 | Plural separated benzene rings in Z moiety | 23 |
| 20080221210 | Thyroid Receptor Agonists - The invention provides compounds of formula (I) or a pharmaceutically acceptable ester, amide, solvate or salt thereof, including a salt of such an ester or amide, and a solvate of such an ester, amide or salt. The invention also provides the use of such compounds in the treatment or prophylaxis of a condition mediated by a thyroid receptor. Formula (I), wherein R | 09-11-2008 |
| 20080306150 | Compounds for the Treatment of Metabolic Disorders - Agents useful for the treatment of various metabolic disorders, such as insulin resistance syndrome, diabetes, polycystic ovary syndrome, hyperlipidemia, fatty liver disease, cachexia, obesity, atherosclerosis and arteriosclerosis are disclosed. Formula (I), wherein n is 1 or 2; m is 0, 1, 2, 3, or 4; q is 0 or 1; t is 0 or 1; R is hydrogen, halo, hydroxy, alkyl having 1 or 2 carbon atoms, perfluoromethyl, alkoxy having 1 or 2 carbon atoms, and perfluoromethoxy; R is alkyl having from 1 to 3 carbon atoms; R | 12-11-2008 |
| 20090069421 | CRYSTAL POLYMORPH OF HYDROXYNOREPHEDRIN DERIVATIVE HYDROCHLORIDE - The present invention provides a novel crystal polymorph of ethyl (−)-2-[4-[2-[[1S,2R]-2-hydroxy-2-(4-hydroxyphenyl)-1-methylethyl]amino]ethyl]-2,5-dimethylphenoxyacetate hydrochloride which can be determined by characteristic diffraction peaks of the powder X-ray diffraction or the like, and obtained from ethyl (−)-2-[4-[2-[[1S,2R]-2-hydroxy-2-(4-hydroxyphenyl)-1-methylethyl]amino]ethyl]-2,5-dimethylphenoxyacetate by a specific method. | 03-12-2009 |
| 20090163589 | Calcilytic Compounds - Novel calcilytic compounds and methods of using them are provided. | 06-25-2009 |
| 20090170938 | FUNGICIDAL ACTIVE INGREDIENT COMBINATION - Active compound combinations comprising an oxime ether derivative of the formula (I) | 07-02-2009 |
| 20100029763 | METHODS TO PREPARE PENTA-1,4-DIEN-3-ONES AND SUBSTITUTED CYCLOHEXANONES AND DERIVATIVES WITH ANTITUMORAL AND ANTIPARASITIC PROPERTIES, THE COMPOUNDS AND THEIR USES - The present invention refers to new derivatives of the penta-1,4-dien-3-ones, as well as their processes of preparation. These compounds present strong antitumoral activity and promising antiparasitic action, behaving as almost atoxic by laboratory assays and also by hystopathologic studies. The present invention refers also to a pharmaceutical composition including the referred compounds, method of treatment for cancer and parasitic diseases. | 02-04-2010 |
| 20100035988 | Methods for activating PPAR gamma-type receptors - Novel biaromatic compounds having the following structural formula (I): | 02-11-2010 |
| 20100286268 | TOPICAL COMPOSITION - The invention relates to beneficial topical pharmaceutical compositions comprising the diclofenac diethylammonium salt in unusually high amounts. Said compositions represent opaque emulsion-gels with unique properties such as high skin penetration, no irritation, high stability, complete dissolution of the active and high pain relief. | 11-11-2010 |
| 20100311829 | Novel Therapeutic Uses of Beta-3 Adrenergic Receptor Agonist Derivatives in Particular to Modulate Apoptosis - The present invention relates to the new therapeutic uses of beta-3 adrenergic receptor agonist derivatives in particular to inhibit apoptosis and treat and/or prevent apoptosis-related diseases and disorders. | 12-09-2010 |
| 20100331410 | Biaryl Amides - A compound of formula: | 12-30-2010 |
| 20110077299 | INHIBITORS OF ALPHA4 MEDIATED CELL ADHESION - The present invention relates to a phenylalanine derivative of Formula (I) wherein X | 03-31-2011 |
| 20110105608 | MODULATORS OF NUCLEAR RECEPTOR CO-REGULATORY PROTEIN BINDING - Disclosed are novel compounds and compositions for inhibition of androgen and estrogen receptor signaling, methods for inhibiting androgen signaling, methods for inhibiting estrogen signaling, methods for inhibiting the interaction between a co-regulatory protein and an androgen or estrogen receptor, and methods for treating cancer. | 05-05-2011 |
| 20110172303 | DEACETYLASE INHIBITORS AND USES THEREOF - The present invention provides novel compounds of formula (I) and pharmaceutical compositions thereof. The inventive compounds are useful as deacetylase inhibitors (e.g., histone deacetylase inhibitors) and may be useful in the treatment of proliferative diseases such as cancer. In particular, the inventive compounds are HDAC6 inhibitors. The invention also provide synthetic methods for preparing the inventive compounds. | 07-14-2011 |
| 20110263704 | Methods of Using Cycloalkylmethylamines - The present invention provides novel cycloalkylmethylamine analogs, and methods of preparing cycloalkylmethylamine analogs. The present invention also provides methods of using cycloalkylmethylamine analogs and compositions of cycloalkylmethylamine analogs. The pharmaceutical compositions of the compounds of the present invention can be advantageously used for treating and/or preventing obesity and obesity related co-morbid indications. | 10-27-2011 |
| 20130210915 | ANTIVIRAL COMPOUNDS - The present invention provides new antiviral compounds and pharmacological compositions comprising these new compounds and their use in the prophylaxis, prevention and treatment of viral infections, particularly adenovirus and herpes virus infections. | 08-15-2013 |
| 20130289109 | INHIBITORS OF ALPHA4 MEDIATED CELL ADHESION - The present invention relates to a phenylalanine derivative of Formula (I) wherein X | 10-31-2013 |
| 20140066504 | ANALOGS AND PRODRUGS OF BUMETANIDE; COMPOSITIONS AND METHODS OF USE - Novel analogs and prodrugs of the loop diuretic bumetanide are described. Pharmaceutical compositions containing bumetanide analogs and prodrugs are also described. These analogs and prodrugs are particularly useful for the treatment and/or prophylaxis of conditions that involve the NKCC cotransporter family (NKCC1 and NKCC2), or the KCC cotransporter family (KCC1, KCC2, KCC3, KCC4), or GABAa receptors. Such conditions include, but are not limited to anxiety disorders, epilepsy, migraine, non-epileptic seizures, sleep disorders, obesity, eating disorders, autism, depression, edema, glaucoma, stroke, ischemia, neuropathic pain, addictive disorders, schizophrenia, psychosis, and tinnitus. | 03-06-2014 |
| 20140128462 | LYOPHILIZED PREPARATION OF CYTOTOXIC DIPEPTIDES - The present invention is directed to novel lyophilized pharmaceutical preparations comprising a cytotoxic dipeptides such as melphalan flufenamide and one or more excipient(s) selected from the group comprising a polysorbate; a polyethylene glycol; β-cyclodextrin; ocyclodextrin; hydroxypropyl-β-cyclodextrin; sulfobutylether-β-cyclodextrin; lactose; benzyl alcohol; disodium succinate; propylene glycol; Cremophor EL; Dimethyl sulfoxide; D-mannitol; Trehalose; Sucrose and an amino acid. This preparation may be further formulated and is useful in cancer therapy. | 05-08-2014 |
| 20140128463 | AMIDE COMPOUND, PREPARATION METHOD AND USES THEREOF - Disclosed are amide compounds, preparation method and uses thereof, specifically, the compounds represented by formula I or pharmaceutically acceptable salts, wherein R | 05-08-2014 |
| 20140221481 | SULFUR DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS - The present invention relates to novel sulfur derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of chemokine receptors. | 08-07-2014 |
| 20150336881 | AMIDE COMPOUND AND USE THEREOF FOR PEST CONTROL - A fused heterocyclic compound represented by formula (1) has an excellent pest control effect. | 11-26-2015 |
| 20150344407 | FENDILINE DERIVATIVES AND METHODS OF USE THEREOF - Disclosed herein are novel derivatives of fendiline, including compounds of the formula: wherein the variables are defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising these derivative compounds. Methods and intermediates useful for making the derivatives, and methods of using the derivatives, for example, for the inhibition of K-Ras plasma membrane localization, and compositions thereof, including for the treatment of cancer, are also provided. | 12-03-2015 |
| 20160031799 | P62-ZZ CHEMICAL INHIBITOR - A method for treating a p62-mediated disease (e.g., multiple myeloma) in a subject, the method comprising administering to the subject a therapeutically effective amount of at least one p62-ZZ inhibitor compound. | 02-04-2016 |
| 514541000 | Aldehyde or ketone in Z or Y radical | 3 |
| 20100204321 | Antitussive and Bronchodilator uses for enaminone ester - The antitussive and bronchodilator use for an enaminone ester relates to the use of ethyl 4-[(4-chlorophenyl)amino]-6-methyl-2-oxocyclohex-3-en-1-oate (also referred to as “enaminone E121”) for treatment of respiratory conditions, and particularly to use of the ester as the active ingredient in a cough suppressant for nonproductive cough. The ester may be used to achieve an antitussive effect, a bronchodilator effect, or both in a patient in need thereof. The ester may be formulated in any desired delivery form (such as a tablet, a capsule, a time-release capsule, a syrup, a liquid, an injection, a spray, or an inhalant), and be combined with any suitable pharmaceutical carrier, vehicles, binders, fillers, disintegrators, lubricants, solubilizers, emulsifiers, surfactants, and other excipients. | 08-12-2010 |
| 20100216881 | Enhydrazone esters for treating asthma, allergy and inflammation - The enhydrazone esters for treating asthma, allergy, and inflammation relate to the use of two cyclohexenone derivatives and pharmaceutically acceptable salts thereof in the treatment of asthma, allergies, and inflammation. The esters have the formula: | 08-26-2010 |
| 20100280108 | Antitumoral Compounds - A compound of general formula (I) | 11-04-2010 |
| 514542000 | Z radical contains two or more nitrogen atoms at least one of which forms a C(=X)N group (X is chalcogen) | 5 |
| 20090036528 | Multifunctional and combinational application of aspartame and or futhan - The present invention is an application, composition, and method of using a pharmaceutically effective amount of aspartame or its primary metabolite aspartyl-phenylalanine in systematic and periodic application or dose as an aspirin (NSAID) substitute, treatment for osteoporosis, and or topical treatment for Rosacea. | 02-05-2009 |
| 20110230555 | Enzyme Inhibitors and the Use Thereof - The present invention provides compounds and methods for the treatment of diseases or disorders such as heart failure, hyperlipidemia, hypercholesterolemia, gonadotropin deficiency, diabetes mellitus, metabolic syndrome, hyperglycemia, insulin resistance, glucose intolerance, obesity, psoriasis, atopic dermatitis, and cancer. | 09-22-2011 |
| 20120277310 | NOVEL CONJUGATES FOR TREATING NEURODEGENERATIVE DISEASES AND DISORDERS - A conjugate comprising L-DOPA covalently linked to at least one γ-aminobutyric acid (GABA) moiety, an ester and/or an addition salt thereof are disclosed, as well as uses thereof for treating a neurodegenerative disease or disorder. | 11-01-2012 |
| 20150291511 | CARBAMOYL HYDRAZINE DERIVATIVES AS FORMYL PEPTIDE MODULATORS - The present invention relates to carbamoyl hydrazine derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of the FPR receptor. | 10-15-2015 |
| 20150322001 | OMEGA-3 ANALOGUES - The present invention relates to new fatty acid analogues and to their use in cancer therapy, including antimetastatic therapy. | 11-12-2015 |
